Patents by Inventor Namita GANDHI

Namita GANDHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating or preventing asthma by administering an IL-4R antagonist
    Patent number: 11845800
    Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: December 19, 2023
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephane C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming
  • METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR
    Publication number: 20230159647
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Application
    Filed: September 23, 2022
    Publication date: May 25, 2023
    Inventors: Neil STAHL, Jamie M. ORENGO, Andrew J. MURPHY, Namita GANDHI, Neil GRAHAM
  • Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
    Patent number: 11485788
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 1, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, Jamie M. Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST
    Publication number: 20220204631
    Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 30, 2022
    Inventors: Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
  • Method of treating an allergy with allergen-specific monoclonal antibodies
    Patent number: 11352417
    Abstract: The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 7, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Namita A. Gandhi, Allen Radin, Ana Kostic, Andrew J. Murphy, George D. Yancopoulos
  • Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
    Patent number: 11214621
    Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 4, 2022
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
  • METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR
    Publication number: 20200299393
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 24, 2020
    Inventors: Neil Stahl, Jamie M. Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor
    Patent number: 10676530
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 9, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, Jamie M. Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor
    Patent number: 10669341
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 2, 2020
    Inventors: Neil Stahl, Jamie M. Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
    Patent number: 10392439
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 27, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, Jamie M Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST
    Publication number: 20190040147
    Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 7, 2019
    Inventors: Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
  • METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST
    Publication number: 20190040146
    Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 7, 2019
    Inventors: Leda Mannent, Gianluca Pirozzi, Allen Radin, Namita A. Gandhi, Robert Evans
  • Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
    Patent number: 10066017
    Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: September 4, 2018
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC
    Inventors: Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
  • Methods for treating nasal polyposis by administering an IL-4R antagonist
    Patent number: 10059771
    Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 28, 2018
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Leda Mannent, Gianluca Pirozzi, Allen Radin, Namita A. Gandhi, Robert Evans
  • Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
    Publication number: 20180094069
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Neil Stahl, Jamie M. Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
    Publication number: 20180094070
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) antagonist such as an anti-IL-4R? antibody.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Neil Stahl, Jamie M. Orengo, Andrew J. Murphy, Namita Gandhi, Neil Graham
  • METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
    Publication number: 20180016343
    Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Application
    Filed: June 20, 2017
    Publication date: January 18, 2018
    Inventors: Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephane C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming
  • Methods for treating or preventing asthma by administering an IL-4R antagonist
    Patent number: 9574004
    Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: February 21, 2017
    Assignees: Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
    Inventors: Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephanie C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming
  • METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST
    Publication number: 20160185866
    Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Application
    Filed: November 13, 2015
    Publication date: June 30, 2016
    Inventors: Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
  • METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST
    Publication number: 20150017182
    Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Application
    Filed: June 20, 2014
    Publication date: January 15, 2015
    Inventors: Leda MANNENT, Gianluca PIROZZI, Allen RADIN, Namita A. GANDHI, Robert EVANS